Single-Center, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Radio-labeled RO4602522 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Sembragiline (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Roche
- 24 Oct 2012 Actual initiation date changed from May 2012 to Jun 2012 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jul 2012 New trial record